EZETIMIBE

Principal Investigators : Dr Milan Gupta, Dr Subodh Verma

Effects of Ezetimibe Add-On to Statin Therapy on Adipokine Production in Obese and Metabolic Syndrome Patients with Atherosclerosis
Schering Investigator-Initiated Research Grant
2007-2008

Ezetimibe P05080

Effects of Ezetimibe Add-On to Statin Therapy on Adipokine Production in Obese and Metabolic Syndrome Patients with Atherosclerosis

Status: Completed

The purpose of this study is to investigate the effects of adding ezetimibe to statin therapy on levels of inflammatory markers and adipokines in patients with atherosclerosis disease and features of the metabolic syndrome, whose LDL-c remains above target (> 2.0 mmol/L) despite statin monotherapy. We hypothesize that the addition of Ezetimibe (10mg per day for 12 weeks) to ongoing statin therapy in patients with atherosclerosis and features of the metabolic syndrome will favourably modify levels of inflammatory biomarkers and adipokines.

Study Design: Time series/single patient design

Intervention: Ezetimibe to all the patients

Length of Study: 1 year

Project Start: 2007

Project Completion: Completed

# of Patients: 50

Patient Population: Patients on statin with atherosclerosis (CHD and/or cerebrovascular disease and/or peripheral arterial disease (PAD))

PRESENTATIONS: None available

PUBLICATIONS

Gupta M., Szmitko P.E., Tsigoulis M., Braga M., Kajil M., Hirjikaka S., Quan A., Teoh H. and Verma S: Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease. JCVP (In Press)

This study was funded by CCRN through an unrestricted investigator initiated research grant from Schering-Plough Canada Inc.

EDUCATIONAL PROGRAMS:


Learn More »

RESEARCH OPPORTUNITIES:


Learn More »

Learn More »


SANSAR

CCRN is partnering with SANSAR to provide community initiatives, implement research projects and support clinical services. Click below for more information

Learn More »